ILiAD Biotechnologies
2012
FOUNDED
PRIVATE
STATUS
Angel
LATEST DEAL TYPE
$8M
LATEST DEAL AMOUNT
1
INVESTORS
Description
Provider of a technology to prevent bordetella pertussis. The company is focused on the eradication of whooping cough by developing an improved pertussis vaccine.
Primary Industry
Biotechnology
Primary Office
- 230 East 15th Street
- Suite 1-A
- New York, NY 10003
- United States
+1 (954) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore ILiAD Biotechnologies’s full profile, request a free trial.
ILiAD Biotechnologies Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Angel (individual) | 13-Apr-2017 | $8M | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 3. Angel (individual) | 13-Nov-2015 | 00000 | 00.000 | Completed | Clinical Trials - Phase 1 | |
| 2. Grant | $10M | $3.81M | Completed | Clinical Trials - Phase 1 | ||
| 1. Angel (individual) | $3.81M | $3.81M | Completed | Clinical Trials - Phase 1 |
ILiAD Biotechnologies Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| European Union | Government | 000 0000 | 000000 0 |